<DOC>
	<DOCNO>NCT01151059</DOCNO>
	<brief_summary>The present study evaluate safety immunogenicity healthy people ( non-elderly adult elderly subject ) one intramuscular ( IM ) dose trivalent subunit inactivate flu vaccine .</brief_summary>
	<brief_title>Safety Immunogenicity One Dose Inactivated Trivalent Flu Vaccine Administered Non-elderly Adult Elderly Subjects</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Males females volunteer 18 year age old , mentally competent , willing able give write informed consent prior study entry Individuals able complain study requirement Individuals good health determine outcome medical history , physical examination clinical judgment investigator . Individuals behavioral cognitive impairment psychiatric disease , opinion investigator , may interfere subject 's ability participate study Individuals serious chronic acute disease ( judgment investigator ) , include limited : cancer , advance congestive heart failure , chronic obstructive pulmonary disease ( COPD ) , autoimmune disease , acute progressive hepatic renal disease , severe neurological psychiatric disorder severe asthma Individuals history anaphylactic reaction and/or serious allergic reaction follow vaccination , proven hypersensitivity component study vaccine ( e.g . eggs/eggs product well ovalbumin , chicken protein , chicken feather , influenza viral protein , kanamycin neomycin sulphate ) Individuals know suspected impairment/alteration immune function result , example , : receipt immunosuppressive therapy within past 60 day full length study , receipt immunostimulants , receipt parenteral immunoglobulin preparation , blood product and/or plasma derivates within past 3 month full length study suspect know human immunodeficiency virus ( HIV ) infection HIVrelated disease Individuals know suspected history drug alcohol abuse Female pregnant nursing ( breastfeed ) mother females childbearing potential plan use acceptable birth control measure whole duration study Individuals history illness , opinion investigator , might interfere result study pose additional risk subject due participation study Individuals within past 6 month , seasonal pandemic laboratory confirm influenza disease receive seasonal pandemic influenza vaccine Individuals acute chronic infection require systemic antibiotic treatment antiviral therapy within last 7 day Individuals experience fever ( i.e. , axillary temperature ≥ 38°C ) within last 3 day intend study vaccination Individuals participate clinical trial another investigational product 4 week prior first study visit intent participate another clinical study time conduct study Individuals receive vaccine within 4 week prior enrollment study planning receive vaccine within 4 week study vaccine Individuals ever receive blood/blood product and/or plasma derivative parenteral immunoglobulin preparation past 12 week full length study Individuals part study personnel close family member conduct study Individuals bleed diathesis condition associate prolonged bleeding time investigator 's opinion would interfere safety subject BMI &gt; 35 kg/m2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>seasonal influenza</keyword>
	<keyword>vaccine</keyword>
</DOC>